Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

Drug policy and human rights in the Middle East and North Africa: Harm reduction, legal environment and public health.

Himmich H, Kazatchkine MD, Stimson GV.

Int J Drug Policy. 2016 May;31:4-5. doi: 10.1016/j.drugpo.2016.04.008. Epub 2016 Apr 12. No abstract available.

PMID:
27131479
2.

Is sub-Saharan Africa ready for pre-exposure prophylaxis?

Bernier A, Gapiya J, Sylla A, Anoma C, Somda M, Dah E, Aranda JF, Himmich H.

Lancet HIV. 2016 Apr;3(4):e154-5. doi: 10.1016/S2352-3018(16)00042-4. No abstract available.

PMID:
27036989
3.

The state of harm reduction in the Middle East and North Africa: A focus on Iran and Morocco.

Himmich H, Madani N.

Int J Drug Policy. 2016 May;31:184-9. doi: 10.1016/j.drugpo.2016.02.013. Epub 2016 Feb 19.

PMID:
27012581
4.

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

INSIGHT START Study Group., Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD.

N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20.

5.

Scaling up combined community-based HIV prevention interventions targeting truck drivers in Morocco: effectiveness on HIV testing and counseling.

Himmich H, Ouarsas L, Hajouji FZ, Lions C, Roux P, Carrieri P.

BMC Infect Dis. 2015 May 5;15:208. doi: 10.1186/s12879-015-0936-6.

6.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group.; Royal Free Hospital Clinic Cohort.; INSIGHT study group.; SMART study group.; ESPRIT study group..

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar 31.

7.

Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.

INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group., Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD.

HIV Med. 2015 Apr;16 Suppl 1:1-9. doi: 10.1111/hiv.12227. No abstract available.

8.

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups.; SILCAAT Scientific Committee..

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.

9.

Factors associated with D-dimer levels in HIV-infected individuals.

Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group.; ESPRIT Study Group.; SILCAAT Scientific Committee..

PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014 Mar 13.

10.

Co-infections with hepatitis B and C viruses in human immunodeficiency virus-infected patients in Morocco.

Rebbani K, Ouladlahsen A, Bensghir A, Akil A, Lamdini H, Issouf H, Brahim I, Kitab B, Fakhir FZ, Wakrim L, Marhoum El Filali K, Himmich H, Ezzikouri S, Benjelloun S.

Clin Microbiol Infect. 2013 Oct;19(10):E454-7. doi: 10.1111/1469-0691.12252. Epub 2013 Jun 3.

11.

Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.

Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group..

PLoS One. 2013;8(2):e56249. doi: 10.1371/journal.pone.0056249. Epub 2013 Feb 15.

12.

Long-term effects of intermittent IL-2 in HIV infection: extended follow-up of the INSIGHT STALWART Study.

Markowitz N, Lopardo G, Wentworth D, Gey D, Babiker A, Fox L, Tavel J; STALWART Study Group..

PLoS One. 2012;7(10):e47506. doi: 10.1371/journal.pone.0047506. Epub 2012 Oct 17.

13.

[Alliance against MDRO: safeguarding antibiotics].

Carlet J, Rambaud C, Pulcini C; l'Alliance contre développement des bactéries multirésistantes (ACdeBMR)..

Ann Fr Anesth Reanim. 2012 Sep;31(9):704-8. doi: 10.1016/j.annfar.2012.07.003. Epub 2012 Aug 24. French.

PMID:
22925945
14.

[Benefit of the rapid test determine HIV1/2 in the clinical diagnosis of HIV infection in Ibn Rochd hospital of Casablanca, Morocco].

Ouladlahsen A, Bensghir R, Karkouri M, Elharti E, Oumzil H, Himmich H, Elfilali KM, Chakib A.

Rev Epidemiol Sante Publique. 2012 Aug;60(4):333-8. doi: 10.1016/j.respe.2012.01.009. Epub 2012 Jul 11. French.

PMID:
22789747
15.

[Causes of death among 91 HIV-infected adults in the era of potent antiretroviral therapy].

Sodqi M, Marih L, Lahsen AO, Bensghir R, Chakib A, Himmich H, El Filali KM.

Presse Med. 2012 Jul;41(7-8):e386-90. doi: 10.1016/j.lpm.2011.12.013. Epub 2012 Feb 18. French.

PMID:
22350063
16.

Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).

Pett SL, Carey C, Lin E, Wentworth D, Lazovski J, Miró JM, Gordin F, Angus B, Rodriguez-Barradas M, Rubio R, Tambussi G, Cooper DA, Emery S; INSIGHT-ESPRIT Study Group..

HIV Med. 2011 Apr;12(4):219-27. doi: 10.1111/j.1468-1293.2010.00875.x. Epub 2010 Aug 31.

17.

Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.

Tavel JA; INSIGHT STALWART Study Group., Babiker A, Fox L, Gey D, Lopardo G, Markowitz N, Paton N, Wentworth D, Wyman N.

PLoS One. 2010 Feb 23;5(2):e9334. doi: 10.1371/journal.pone.0009334.

18.

Interleukin-2 therapy in patients with HIV infection.

INSIGHT-ESPRIT Study Group.; SILCAAT Scientific Committee., Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D.

N Engl J Med. 2009 Oct 15;361(16):1548-59. doi: 10.1056/NEJMoa0903175.

19.

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.

Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group..

J Infect Dis. 2009 Sep 15;200(6):973-83. doi: 10.1086/605447.

20.

Interruption of antiretroviral therapy is associated with increased plasma cystatin C.

Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group..

AIDS. 2009 Jan 2;23(1):71-82. doi: 10.1097/QAD.0b013e32831cc129.

Supplemental Content

Loading ...
Support Center